Adamax vs Noopept
Emerging vs Moderate Research
monitor Researched · 90% Both enhance cognition through different mechanisms but share BDNF upregulation; start lower doses and monitor for overstimulation.
Molecular Data
Adamax Noopept
Weight 1,032.24 Da 318.37 Da
Half-life 8-10 hours ~30 minutes (oral), active metabolite cycloprolylglycine persists longer
Chain 9 amino acids (with modifications) —
Type Modified heptapeptide derivative Dipeptide derivative (C17H22N2O4)
Key Benefits
Adamax
01 Enhanced cognitive function and mental clarity
02 Improved focus and complex task handling
03 Neuroprotection against oxidative stress
04 Neuroplasticity support through BDNF upregulation
05 Potential mood enhancement
06 Stress resilience through HPA axis modulation
Noopept
01 Enhanced memory formation and consolidation through upregulation of BDNF and NGF
02 Neuroprotective effects against oxidative stress, excitotoxicity, and amyloid-beta toxicity
03 Improved learning capacity and information retrieval via AMPA/NMDA receptor modulation
04 Ultra-low effective dose (10-30 mg) compared to classical racetams, reducing pill burden and cost
05 Anxiolytic properties observed at standard nootropic doses without sedation
06 Fast onset of subjective effects despite the short parent compound half-life, due to active metabolite persistence
Dosing Protocols
Adamax
200-300mcg / Once daily, or twice for enhanced neuroprotection
Cognitive Enhancement 200-300mcg 1x daily
Neuroprotection 300mcg 1-2x daily
Mood Support 200mcg 1x daily (morning)
Initial Trial 100-200mcg 1x daily
Noopept
10-30 mg/day / Split AM/PM (sublingual or oral)
Side Effects
Adamax
Headaches (particularly at higher doses)
Insomnia or sleep disruption
Anxiety or overstimulation
Cardiovascular effects (elevated blood pressure, palpitations)
Noopept
Headache (most common side effect, typically caused by insufficient choline intake -- co-supplementation with Alpha-GPC or CDP-Choline usually resolves this)
Irritability and restlessness, particularly at doses exceeding 30 mg/day
Insomnia if taken too late in the day
Mild gastrointestinal discomfort when taken on an empty stomach
Contraindications
Pregnancy and breastfeeding
Cardiovascular conditions (without medical supervision)
Severe anxiety disorders
Uncontrolled hypertension
Known hypersensitivity to Noopept or related compounds
Severe hepatic impairment (metabolized by the liver)
Severe renal impairment
Pregnancy and breastfeeding (insufficient safety data)
Hypertension that is poorly controlled (due to potential mild pressor effects)
Research Evidence
Adamax Noopept
Status Emerging Moderate Research
References 4 studies 4 studies
Latest 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.